Edgewise Therapeutics Inc
$ 30.09
2.66%
23 Feb - close price
- Market Cap 3,185,581,000 USD
- Current Price $ 30.09
- High / Low $ 30.15 / 28.98
- Stock P/E N/A
- Book Value 5.28
- EPS -1.57
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -0.30 %
- 52 Week High 31.29
- 52 Week Low 10.60
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$38.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | 0 | -0.39 | -0.34 | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 | -0.47 | -0.41 | -0.34 | -0.36 |
| Estimated EPS | -0.4359 | -0.4 | -0.42 | -0.4211 | -0.4222 | -0.37 | -0.34 | -0.39 | -0.43 | -0.4 | -0.4 | -0.36 |
| Surprise | 0.4359 | 0.01 | 0.08 | -0.0089 | 0.0022 | 0.01 | 0 | 0.06 | -0.04 | -0.01 | 0.06 | 0 |
| Surprise Percentage | 100% | 2.5% | 19.0476% | -2.1135% | 0.5211% | 2.7027% | 0% | 15.3846% | -9.3023% | -2.5% | 15% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.43 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EWTX
2026-02-20 08:57:39
Aberdeen Group plc significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 39.8% in Q3, holding 619,878 shares valued at $10.05 million. Other institutional investors also substantially raised their positions, indicating strong institutional accumulation. Despite a director's insider sale, analysts maintain a "Moderate Buy" rating with a consensus price target of $36.67, reflecting bullish sentiment towards the biopharmaceutical company.
2026-02-15 16:19:51
Edgewise Therapeutics (NASDAQ:EWTX) has received a "Moderate Buy" consensus rating from ten brokerages, with an average 1-year price target of $36.67. This comes alongside recent insider selling by a director, Badreddin Edris, who reduced his holdings by 85%, and significant institutional buying from firms like Morgan Stanley and Marshall Wace. The clinical-stage biopharmaceutical company, trading near its 12-month high, is focused on developing precision medicines for rare diseases, including EWTX-101 for proteinuric kidney diseases.
2026-02-15 07:27:29
Wall Street Zen has upgraded Edgewise Therapeutics (NASDAQ:EWTX) from a "sell" to a "hold" rating. Despite this, MarketBeat reports a consensus "Moderate Buy" rating with a target price of $36.67. Insider trading activity shows Director Badreddin Edris sold a significant portion of his holdings, while various institutional investors have adjusted their stakes in the biopharmaceutical company.
2026-02-13 21:57:34
Edgewise Therapeutics provided updates on its pipeline at Guggenheim's 2026 Healthcare Innovations Conference, highlighting upcoming milestones for its cardiac and neuromuscular programs. The company is on track for a pivotal Phase 3 readout for sevasemten in Becker muscular dystrophy in Q4 2026 and plans to initiate a Phase 3 program for EDG-7500 in hypertrophic cardiomyopathy (HCM) after disclosing Part D results covering both obstructive and non-obstructive HCM. Edgewise also addressed earlier atrial fibrillation concerns related to its HCM program, detailing protocol and screening changes that have shown no AFib burden in recent monitoring.
2026-02-12 20:59:01
Edgewise Therapeutics (EWTX) is poised for significant momentum driven by upcoming Phase III readout for sevasemten in Becker and CIRRUS Part D data in HCM. The company also plans Phase I initiation for EDG-15400. Enhanced trial designs and strong patient retention underpin strong commercial prospects, with Phase III HCM trials expected in Q4.
2026-02-10 23:57:44
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Edgewise Therapeutics (EWTX) with a price target of $51.00. This follows another Buy rating from Truist Financial, though TipRanks – OpenAI upgraded the stock to a Hold. Despite a reported GAAP net loss of $40.67 million for the last quarter, insider sentiment is neutral, with one director recently purchasing 10,700 shares.
